Note 5 - Related Party Transactions	12 Months Ended
Dec. 31, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	5. Related Party Transactions On May 23, 2016, Amarillo Biosciences, Inc. (“ABI”), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. (“ACTS Global”), a Taiwan Corporation, the Agent. ABI advances funds to ACTS Global to be utilized and /or expended by ACTS Global solely as instructed by ABI. Additional advances may be made by ABI to ACTS Global as necessary. For their services, ACTS Global, is be paid by ABI, one percent ( 1% ) of the Principal’s services expended by the Agent at the Principal’s direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values of the service rendered. As of December 31, 2017, a balance of $58,135 is in the ACTS Global account for the benefit of the Company, which is included on the Company Balance Sheet in Advance to Related Party. On December 20, 2016, effective January 1, 2017, the Board of Directors approved a resolution whereby Dr. Chen's annual compensation was changed to $90,000 cash per annum and $75,000 per annum payable in the Company's unregistered, voting common stock. The Board also approved the change in compensation to Bernard Cohen to $65,000 cash per annum and $10,000 per annum payable in the Company's unregistered, voting common stock. The cash compensation is to be paid on the normal payroll cycle of 15th and 31st of each month and stock compensation to be paid quarterly. Shares are to be priced at the average of all trading day closing quotes on the OTC-BB for the month preceding date of issuance, with such shares to be issued on the first business day after the close of each calendar quarter or as soon thereafter as practicable. During the period ended September 30, 2017, the Company has issued an aggregate of 535,525 shares of common stock valued at $122,500. As of September 30, 2017, the Company has accrued $21,250 in Accounts Payable and Accrued Expenses representing fourth quarter shares that have not been issued.

Related Party

Transactions

May 23, 2016,

Amarillo Biosciences, Inc. (“ABI”), the Principal, entered into an Agency and Service Agreement with ACTS Global Healthcare, Inc. (“ACTS Global”), a Taiwan Corporation, the Agent. ABI advances funds to ACTS Global to be utilized and /or expended by ACTS Global solely as instructed by ABI. Additional advances

may

be made by ABI to ACTS Global as necessary. For their services, ACTS Global, is be paid by ABI,

one

percent (

) of the Principal’s services expended by the Agent at the Principal’s direction. Any other services rendered by the Agent will be paid for by the Principal based on comparable and/or reasonable values of the service rendered. As of

December 31, 2017,

a balance of

$58,135

is in the ACTS Global account for the benefit of the Company, which is included on the Company Balance Sheet in Advance to Related Party.

December 20, 2016,

effective

January 1, 2017,

the Board of Directors approved a resolution whereby Dr. Chen's annual compensation was changed to

$90,000

cash per annum and

$75,000

per annum payable in the Company's unregistered, voting common stock. The Board also approved the change in compensation to Bernard Cohen to

$65,000

cash per annum and

$10,000

per annum payable in the Company's unregistered, voting common stock. The cash compensation is to be paid on the normal payroll cycle of

15th

and

31st

of each month and stock compensation to be paid quarterly. Shares are to be priced at the average of all trading day closing quotes on the OTC-BB for the month preceding date of issuance, with such shares to be issued on the

first

business day after the close of each calendar quarter or as soon thereafter as practicable. During the period ended

September 30, 2017,

the Company has issued an aggregate of

535,525

shares of common stock valued at

$122,500.

As of

September 30, 2017,

the Company has accrued

$21,250

in Accounts Payable and Accrued Expenses representing

fourth

quarter shares that have

not

been issued.